Amide Technologies, a Cambridge, MA-based biotech that synthesizes challenging peptides, $16.5M in total funding.
The round included a $7.5M Series A Extension investment closed in July 2023 led by Engine Ventures with participation from Forcefield Venture Fund. Previous rounds included a $3.55M Series A, also led by Engine Ventures, and a $5.45M Seed Round led by Biological Engineering Ventures.
The company intends to use the funds to scale operations, build additional instrumentation, and launch new pilot programs with pharmaceutical partners.
Spun out of MIT and led by Amide CEO Mark Simon, PhD, Amide Technologies is a biotech startup offering on-demand complex peptide manufacturing at high speed. Developed in the Pentelute Lab within MIT’s Department of Chemistry, the company’s complex peptide manufacturing platform expands what is possible in peptide drug design by offering reliable linear synthesis of peptides up to 120 amino acids, improving upon SPPS technology’s maximum of around 40 amino acids. Amide’s Automated Fast Flow Peptide Synthesis (AFPS) method uses heat and flow to enable synthesis of complex peptides that can’t be naturally expressed, such as mirror image proteins and branched structures.
Amide currently works with organizations including The Salk Institute and Velia Therapeutics to manufacture peptides not manufacturable by other means, such as mirror image enzymes and multimeric polyamides.
Simon was a Ginkgo Bioworks alum who led the MIT team that developed Amide’s platform technology from 2011 to 2017. The company also hired as COO Philip Dixon, a former CIO of Silverrail Technologies and a veteran of the Flights and M&A teams at Google, where he landed after helping shepherd ITA Software to an acquisition in 2011. ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD.
FinSMEs
14/12/2023